Gastroenterology
Volume 136, Issue 2 , Pages 477-485.e11 , February 2009

Elevated Serum Alanine Aminotransferase and γ-Glutamyltransferase and Mortality in the United States Population

  • Constance E. Ruhl

      Affiliations

    • Social & Scientific Systems, Inc, Silver Spring, Maryland
    • Corresponding Author InformationAddress requests for reprints to: Constance E. Ruhl, MD, PhD, Social & Scientific Systems, Inc, 8757 Georgia Avenue, 12th floor, Silver Spring, Maryland 20910. Phone: (301) 628-3272; fax: (301) 628-3201
    • ,
  • James E. Everhart

      Affiliations

    • National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland

Received 21 April 2008 ,Accepted 9 October 2008.

References 

  1. Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004;328:983
  2. Nakamura K, Okamura T, Kanda H, et al. The value of combining serum alanine aminotransferase levels and body mass index to predict mortality and medical costs: a 10-year follow-up study of National Health Insurance in Shiga, Japan. J Epidemiol. 2006;16:15–20
  3. Lee TH, Kim WR, Benson JT, et al. Serum aminotransferase activity and mortality risk in a United States community. Hepatology. 2008;47:880–887
  4. Arndt V, Brenner H, Rothenbacher D, et al. Elevated liver enzyme activity in construction workers: prevalence and impact on early retirement and all-cause mortality. Int Arch Occup Environ Health. 1998;71:405–412
  5. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis. 2007;191:391–396
  6. Fraser A, Ebrahim S, Smith GD, et al. A comparison of associations of alanine aminotransferase and gamma-glutamyltransferase with fasting glucose, fasting insulin, and glycated hemoglobin in women with and without diabetes. Hepatology. 2007;46:158–165
  7. Fraser A, Harris R, Sattar N, et al. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol. 2007;27:2729–2735
  8. Kazemi-Shirazi L, Endler G, Winkler S, et al. Gamma glutamyltransferase and long-term survival: is it just the liver?. Clin Chem. 2007;53:940–946
  9. Kim DJ, Noh JH, Cho NH, et al. Serum gamma-glutamyltransferase within its normal concentration range is related to the presence of diabetes and cardiovascular risk factors. Diabet Med. 2005;22:1134–1140
  10. Lee DH, Jacobs DR, Gross M, et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2003;49:1358–1366
  11. Lee DH, Silventoinen K, Jacobs DR, et al. Gamma-glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab. 2004;89:5410–5414
  12. Lee DH, Silventoinen K, Hu G, et al. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur Heart J. 2006;27:2170–2176
  13. Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27:127–133
  14. Meisinger C, Doring A, Schneider A, et al. Serum gamma-glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population. Atherosclerosis. 2006;189:297–302
  15. Monami M, Bardini G, Lamanna C, et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism. 2008;57:387–392
  16. Ruttmann E, Brant LJ, Concin H, et al. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation. 2005;112:2130–2137
  17. Sakuta H, Suzuki T, Yasuda H, et al. Gamma-glutamyl transferase and metabolic risk factors for cardiovascular disease. Intern Med. 2005;44:538–541
  18. Strasak AM, Rapp K, Brant LJ, et al. Association of gamma-glutamyltransferase and risk of cancer incidence in men: a prospective study. Cancer Res. 2008;68:3970–3977
  19. Strasak AM, Pfeiffer RM, Klenk J, et al. Prospective study of the association of gamma-glutamyltransferase with cancer incidence in women. Int J Cancer. 2008;123:1902–1906
  20. Ulmer H, Kelleher C, Diem G, et al. Why Eve is not Adam: prospective follow-up in 149650 women and men of cholesterol and other risk factors related to cardiovascular and all-cause mortality. J Womens Health (Larchmt). 2004;13:41–53
  21. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94 (DHHS Publication No. [PHS] 94-1308). Hyattsville, MD: National Center for Health Statistics; 1994;
  22. Gunter EW, Lewis BG, Koncikowski SM. Laboratory procedures used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Environmental Health, National Center for Health Statistics; 1996;
  23. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10
  24. NCHS. NHANES III Linked Mortality File matching methodology (2005). http://www.cdc.gov/nchs/data/datalinkage/matching_methodology_nhanes3_final.pdfAccessed August 20, 2008
  25. Menke A, Muntner P, Batuman V, et al. Blood lead below 0.48 μmol/L (10 μg/dL) and mortality among US adults. Circulation. 2006;114:1388–1394
  26. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124:71–79
  27. Ruhl CE, Everhart JE. Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States. Gastroenterology. 2003;124:1821–1829
  28. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2005;128:24–32
  29. Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc. 1993;25:71–80
  30. Michels KB, Willett WC, Fuchs CS, et al. Coffee, tea, and caffeine consumption and incidence of colon and rectal cancer. J Natl Cancer Inst. 2005;97:282–292
  31. National Health and Nutrition Examination Survey III: body measurements (anthropometry). Rockville, MD: Westat; 1988;
  32. National Health and Nutrition Examination Survey III cycle 2: pulse and blood pressure procedures for household inteviewers. Rockville, MD: Westat; 1989;
  33. Kleinbaum DG. Survival analysis: a self-learning text. New York, NY: Springer; 1996;
  34. Breslow NE, Day NE. Statistical methods in cancer research: the design and analysis of cohort studies. In: Lyon, France: International Agency for Research on Cancer; 1987;p. 48–79
  35. Kim WR, Flamm SL, Di Bisceglie AM, et al. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47:1363–1370
  36. Mazza A, Casiglia E, Scarpa R, et al. Predictors of cancer mortality in elderly subjects. Eur J Epidemiol. 1999;15:421–427
  37. Ohlson LO, Larsson B, Bjorntorp P, et al. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus (Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913). Diabetologia. 1988;31:798–805
  38. Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:1889–1895
  39. Sattar N, Scherbakova O, Ford I, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes. 2004;53:2855–2860
  40. Hanley AJ, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes. 2004;53:2623–2632
  41. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2004;27:1427–1432
  42. Wannamethee SG, Shaper AG, Lennon L, et al. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care. 2005;28:2913–2918
  43. Nannipieri M, Gonzales C, Baldi S, et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City Diabetes Study. Diabetes Care. 2005;28:1757–1762
  44. Schindhelm RK, Dekker JM, Nijpels G, et al. No independent association of alanine aminotransferase with risk of future type 2 diabetes in the Hoorn Study. Diabetes Care. 2005;28:2812
  45. Andre P, Balkau B, Born C, et al. Hepatic markers and development of type 2 diabetes in middle aged men and women: a three-year follow-up study (The D.E.S.I.R. Study (Data from an Epidemiological Study on the Insulin Resistance syndrome)). Diabetes Metab. 2005;31:542–550
  46. Brenner H, Rothenbacher D, Arndt V, et al. Distribution, determinants, and prognostic value of gamma-glutamyltransferase for all-cause mortality in a cohort of construction workers from southern Germany. Prev Med. 1997;26:305–310
  47. Lee DH, Blomhoff R, Jacobs DR. Is serum gamma glutamyltransferase a marker of oxidative stress?. Free Radic Res. 2004;38:535–539
  48. Lim JS, Yang JH, Chun BY, et al. Is serum gamma-glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress?. Free Radic Biol Med. 2004;37:1018–1023
  49. Lee DH, Jacobs DR. Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis. 2005;178:327–330
  50. Pompella A, Emdin M, Passino C, et al. The significance of serum gamma-glutamyltransferase in cardiovascular diseases. Clin Chem Lab Med. 2004;42:1085–1091
  51. Kang YH, Min HK, Son SM, et al. The association of serum gamma glutamyltransferase with components of the metabolic syndrome in the Korean adults. Diabetes Res Clin Pract. 2007;77:306–313
  52. Lee DH, Ha MH, Kim JH, et al. Gamma-glutamyltransferase and diabetes—a 4 year follow-up study. Diabetologia. 2003;46:359–364
  53. Lim JS, Lee DH, Park JY, et al. A strong interaction between serum gamma-glutamyltransferase and obesity on the risk of prevalent type 2 diabetes: results from the Third National Health and Nutrition Examination Survey. Clin Chem. 2007;53:1092–1098
  54. Pompella A, De Tata V, Paolicchi A, Zunino F. Expression of gamma-glutamyltransferase in cancer cells and its significance in drug resistance. Biochem Pharmacol. 2006;71:231–238
  55. Arslan N, Buyukgebiz B, Ozturk Y, et al. Fatty liver in obese children: prevalence and correlation with anthropometric measurements and hyperlipidemia. Turk J Pediatr. 2005;47:23–27
  56. Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33
  57. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med. 2000;132:112–117
  58. Benini F, Pigozzi MG, Baisini O, et al. Increased serum gamma-glutamyl-transpeptidase concentration is associated with nonalcoholic steatosis and not with cholestasis in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2007;22:1621–1626
  59. Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg. 2006;16:1278–1286
  60. Poynard T, Zourabichvili O, Hilpert G, et al. Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients. Hepatology. 1984;4:324–327
  61. Kulkarni BR, Brancati FL, Seeff LB, et al. A systematic review of the stability of serum alanine aminotransferase and aspartate aminotransferase in storage conditions. Hepatology. 2004;40(Suppl 1):715A

 Supported by a contract from the National Institute of Diabetes and Digestive and Kidney Diseases (HHSN267200700001G).

 The authors disclose no conflicts.

PII: S0016-5085(08)01890-8

doi: 10.1053/j.gastro.2008.10.052

Gastroenterology
Volume 136, Issue 2 , Pages 477-485.e11 , February 2009

Article Tools